논문 15 페이지 | PnH

최근소식

회사소개 사업소개 치료기술 암종별치료 최근소식 고객센터

논문 치료사례 동영상게시판 사진게시판

논문

번호 제목 날짜

210

Proceedings of the National Academy of Sciences:Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class

Proceedings of the National Academy of Sciences:Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class
2024-05-31
209

2024년 Cell Reports Medicine :Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism

2024년 Cell Reports Medicine :Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism
2024-05-31
208

2024년 Nature :Senolytic CAR-T cells reverse senescence-associated pathologies

2024년 Nature :Senolytic CAR-T cells reverse senescence-associated pathologies
2024-05-31
207

2024년 FDA승인된 CAR-T세포치료 와 중국에서 승인된 CAR-T세포치료

2024년 FDA승인된 CAR-T세포치료 와 중국에서 승인된 CAR-T세포치료
2024-05-31
206

2024년 Nature Medicine:Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

2024년 Nature Medicine:Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
2024-05-31
205

2024년 Cancer Research:FAM3C in cancer-associated adipocytes promotes breast cancer cell survival and metastasis

2024년 Cancer Research:FAM3C in cancer-associated adipocytes promotes breast cancer cell survival and metastasis
2024-05-31
204

2024년 폐암 및 기타 고형 종양에 대한 세계 최초의 4세대 TCR-T 치료를 NMPA로부터 임상 승인을 받았습니다.

2024년 폐암 및 기타 고형 종양에 대한 세계 최초의 4세대 TCR-T 치료를 NMPA로부터 임상 승인을 받았습니다.
2024-05-31
203

2024년 Nature Biotechnology:IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases

2024년 Nature Biotechnology:IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
2024-05-31
202

2024년 Cell Discovery :Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma

2024년 Cell Discovery :Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma
2024-05-31
201

2024년 Blood Journal:Anti-tumor Efficacy and Safety of Unedited Autologous CD5.CAR T cells in Relapsed/Refractory Mature T-cell Lymphomas

2024년 Blood Journal:Anti-tumor Efficacy and Safety of Unedited Autologous CD5.CAR T cells in Relapsed/Refractory Mature T-cell Lymphomas
2024-05-31